# Pivotal Study of N-acetyl-L-leucine for CACNA1A

> **NCT07221292** · PHASE3 · NOT_YET_RECRUITING · sponsor: **IntraBio Inc** · enrollment: 60 (estimated)

## Conditions studied

- CACNA1A
- Spinocerebellar Ataxia Type 6
- Episodic Ataxia Type 2
- Familial Hemiplegic Migraine-1

## Interventions

- **DRUG:** N-Acetyl-L-Leucine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07221292
- **Lead sponsor:** IntraBio Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221292, "Pivotal Study of N-acetyl-L-leucine for CACNA1A". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*